The Acetylated 2,3,5,4′-Tetrahydroxystilbene-2-O-β-<scp>d</scp>-Glucoside Improved Pharmacokinetics and Enhanced Anti-Osteoporosis Effects
Background: Osteoporosis has emerged as a significant global public health concern, predominantly affecting postmenopausal women. Its pathogenesis is intricate and the disease course is protracted, imposing substantial medical burden on both society and individuals. Objective: To investigate the effects of 2,3,5,4′-tetrahydroxystilbene-2-O-β-d-glucoside (TSG) and acetylated-TSG (Ac-TSG) on osteoblast viability, in vivo pharmacokinetics in rats and anti-osteoporotic effects in ovariectomized rat model. Methods: Ac-TSG was obtained by acetylation of TSG, and the purity and structure of Ac-TSG were determined by HPLC and 1 H NMR. The effects of TSG and Ac-TSG on MC3T3-E1 cell viability, pharmacokinetics in rats, blood biochemical indexes of OVX model rats were detected. Hematoxylin–eosin (HE) staining was used to observe bone tissue morphology, tartrate-resistant acid phosphatase (TRAP) staining was used to observe osteoclast morphology, micro-CT was used to perform three-dimensional reconstruction of femur, and femur parameters were analyzed. Results: The structure of the compound is Ac-TSG and the purity is more than 98%. Both TSG and Ac-TSG could reduce the damage of oxidative stress to MC3T3-E1 cells and effectively improve the levels of Ca, P, ALP and BGP in serum of OVX rats. Compared with TSG, Ac-TSG has a longer action time in vivo and can improve the femoral structure, the number of trabecular bone and the number of osteoclasts in rats. Conclusion: Ac-TSG conferred protection to MC3T3-E1 cells against oxidative stress-induced damage and enhanced their bioavailability. Simultaneously, Ac-TSG ameliorated abnormal bone metabolism and mitigated bone microstructural changes in OVX rats, exhibiting a protective effect against osteoporosis.
Authors
- Wenxin Wei (ORCID: https://orcid.org/0000-0002-1809-1460)
- Jianshu Liu (ORCID: https://orcid.org/0000-0002-7199-9224)
- Wei Lan
- Feng Liu (ORCID: https://orcid.org/0000-0001-7811-038X)
- Xingyu Li (ORCID: https://orcid.org/0000-0001-5801-7989)
- Feng Gao (ORCID: https://orcid.org/0000-0002-5294-4033)
- Peifeng Wei (ORCID: https://orcid.org/0000-0002-8652-5312)
- Yuqian Yang (ORCID: https://orcid.org/0000-0003-3395-4671)
- Jing Wang (ORCID: https://orcid.org/0000-0003-0843-0358)
- Hong Wang
Institutions
- Nanchang University (CN)
- Xinjiang Medical University (CN)
- Shaanxi Science and Technology Department (CN)
- Buchang Pharma (China) (CN)
- Shaanxi University of Chinese Medicine (CN)
Publication Details
- Journal
- Natural Product Communications
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1177/1934578x241296419
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00